Charlie Health vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual intensive outpatient mental health treatment for adolescents and young adults, Bozeman MT, raised $55M+. Addresses crisis-level care gaps via virtual IOP.
About
Charlie Health is a Bozeman, Montana-based virtual mental health company founded in 2020 that provides intensive outpatient program (IOP) care for adolescents, young adults, and families experiencing mental health crises. The company has raised over $55 million and targets the significant care gap between inpatient psychiatric hospitalization and standard outpatient therapy — a level of care that has historically been difficult to access, particularly outside major urban centers.\n\nCharlie Health's virtual IOP model delivers nine or more hours of structured group and individual therapy per week through a telehealth platform, allowing clients to receive high-intensity care from home while maintaining school or work routines. The clinical approach combines dialectical behavior therapy (DBT), cognitive behavioral therapy (CBT), and trauma-informed care, with treatment teams including licensed therapists, psychiatrists, and care coordinators. Programs are designed for adolescents aged 11 to 17 and young adults aged 18 to 26 presenting with depression, anxiety, trauma, self-harm, and suicidality.\n\nThe company accepts insurance from most major carriers, a deliberate strategic choice to reach underserved populations who cannot afford self-pay intensive treatment. Charlie Health's telehealth delivery model gives it geographic reach into rural and suburban communities where brick-and-mortar IOPs are scarce, positioning the company as an infrastructure solution for the adolescent mental health crisis that intensified during the COVID-19 pandemic.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.